menu
    • menu
    [{"orgOrder":0,"company":"TRON Group","sponsor":"Nanopharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"MALAYSIA","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"TRON Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRON Group \/ Nanopharmaceutics","highestDevelopmentStatusID":"10","companyTruncated":"TRON Group \/ Nanopharmaceutics"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanopharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanopharmaceutics \/ Not Applicable"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nanopharmaceutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Nanopharmaceutics \/ Northwestern University"}]

    Find Clinical Drug Pipeline Developments & Deals for 3-aminopyridine-2-carboxaldehyde thiosemicarbazone

    Menu

    3-aminopyridine-2-carboxaldehyde thiosemicarbazone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanopharmaceutics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Nanopharmaceutics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanopharmaceutics and Northwestern Start Phase I Study of Oral Triapine® for Glioblastoma

                            Details : Oral Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) in combination with temozolomide is being evaluated in the early-stage trial for recurrent glioblastoma.

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2024

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanopharmaceutics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Nanopharmaceutics

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Spons...

                            Details : Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer.

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2022

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TRON Group

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed

                            TRON Group

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Nanopharmaceutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement

                            Details : The new company's pipeline includes 10 clinical-stage and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infe...

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 11, 2022

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Nanopharmaceutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth